Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q3 2025

Type / Class
Equity / Ordinary Shares, no par value
Symbol
CANF on NYSE
Shares outstanding
3,838,602,439
Price per share
$0.31
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
1,538,481
Total reported value
$952,611
% of total 13F portfolios
0%
Share change
+634,597
Value change
+$392,863
Number of holders
15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Orca Capital AG 4.1% -56% $188,859,240 -$261,140,760 157,382,700 -58% Orca Capital AG 22 Apr 2025
ARMISTICE CAPITAL, LLC 5% $528,506 440,422 Armistice Capital, LLC 31 Dec 2024

As of 30 Sep 2025, 15 institutional investors reported holding 1,538,481 shares of Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF). This represents 0.04% of the company’s total 3,838,602,439 outstanding shares.

Institutional Holders of Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 1,538,481 $952,611 +$392,863 $0.62 15
2025 Q2 904,884 $950,122 +$805,185 $1.05 15
2025 Q1 131,231 $193,878 +$24,967 $1.48 13
2024 Q4 114,427 $185,941 -$1,330,864 $1.62 13
2024 Q3 754,233 $1,516,004 +$242,709 $2.01 11
2024 Q2 627,823 $1,619,070 +$392,788 $2.58 11
2024 Q1 477,583 $1,060,150 +$519,387 $2.22 8
2023 Q4 243,810 $536,298 +$381,921 $2.20 8
2023 Q3 67,662 $179,198 +$34,520 $2.65 9
2023 Q2 54,615 $167,672 -$705,135 $3.07 6
2023 Q1 368,327 $843,444 +$843,444 $2.29 7